Dual Bifunctional Vectors for rAAV Production Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The baculovirus expression system faces challenges in large-scale production of recombinant adeno-associated virus (rAAV) vectors due to instability and inefficiencies, particularly in achieving optimal expression levels and stoichiometry of Rep and capsid proteins, leading to suboptimal yields and quality of the produced vectors.
Innovation Solution
The use of DuoBac system with dual expression cassettes for Rep and capsid proteins, optimized promoter combinations, and codon bias adjustments to improve the timing and quantity of protein expression, along with the introduction of a transgene flanked by parvoviral inverted terminal repeats, enhances the production of recombinant parvoviral vectors by ensuring simultaneous infection and reducing homologous recombination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the baculovirus expression system is used for large-scale production of rAAV vectors, then high protein expression levels and scalability are achieved, but instability of production levels and passage effect occur due to recombination between repeated homologous sequences
Solution Approach 1:
The patent divides the expression system into multiple independent baculovirus vectors, each carrying specific genes (AAV Rep genes, AAV Cap genes, and transgene). This segmentation prevents recombination between repeated homologous sequences by distributing them across separate vectors, thereby maintaining production stability while preserving high expression levels.
2Adaptability or versatility
If three separate baculoviruses are used for co-infection (TripleBac system), then Rep, Cap, and transgene expression cassettes are delivered, but non-simultaneous infection occurs reducing production efficiency
Solution Approach 1:
The patent merges multiple expression cassettes into single baculovirus vectors. Specifically, one vector contains both AAV Rep expression cassette and AAV Cap expression cassette, another vector contains AAV Cap expression cassette and transgene expression cassette. This merging ensures simultaneous delivery of all necessary components in a single infection event, improving AAV yield while maintaining the ability to deliver diverse expression cassettes.
3Quantity of substance
If transient chemical transfection of plasmids into Hek293 cells is used, then high titer AAV material is produced, but the system is less suitable for scale-up due to high cost and adaptation requirements
Solution Approach 1:
The patent uses baculovirus vectors as self-replicating copying systems that can be amplified alongside insect cells grown in suspension. The baculovirus DNA replicates autonomously in insect cells, allowing for easy scale-up without the need for plasmid production or cell adaptation. This copying mechanism maintains high AAV titer production while dramatically improving ease of manufacture and scalability compared to transient transfection methods.
Data Source
AI summary
The present invention relates novel combinations of nucleic acid constructs for the production of recombinant parvoviral gene therapy vectors. In particular the invention relates a combination preferably no more than two construct, the first construct expressing both the parvoviral Cap and Rep proteins, and the second construct at least comprising the transgene flanked ITRs and optionally again comprising an expression cassette forthe Cap proteins. The nucleic acid constructs are preferably baculoviral vectors for the production of rAAV in insect cells.